Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: a retrospective follow-up study.
Drug-resistant tuberculosis
Incidence
Lost to follow-up
Predictors
Retrospective study
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
18 Sep 2019
18 Sep 2019
Historique:
received:
18
12
2018
accepted:
09
09
2019
entrez:
20
9
2019
pubmed:
20
9
2019
medline:
27
11
2019
Statut:
epublish
Résumé
The emergence of Drug-Resistance Tuberculosis (DR-TB) is an increasing global public health problem. Lost to Follow-up (LTFU) from DR-TB treatment remains a major barrier to tuberculosis epidemic control and better treatment outcome. In Ethiopia, evidences on the incidence and predictors of LTFU are scarce. Thus, this study aimed to determine the incidence and identify the predictors of LTFU among DR-TB patients. A retrospective follow-up study was conducted among a total of 332 DR-TB patients at the University of Gondar comprehensive specialized hospital. Data were retrieved from patient records from September 2010 to December 2017 and entered in to Epi-data 4.2.0.0 and analysed using Stata14.1 software. The risk was estimated using the Nelson-Aalen cumulative hazard curve. A log-rank test was used for survival comparisons between categories of independent variables. The Gompertz regression model was fitted, and hazard ratio with a 95% confidence interval (CI) was used to measure the strength of associations. Variables with less than 0.05 p-values in the multivariable model were considered as significantly associated with LTFU. Among a total of 332 patient records reviewed, 206 (62.05%) were male. The median age was 30 years (Inter Quartile Range (IQR): 23-40). Forty-one (12.35%) of the participants had no history of TB treatment, while a quarter of were TB-HIV co-infected. Closely all (92.17%) of the patients had pulmonary tuberculosis. The median follow up time was 20.37 months (IQR: 11.02, 21.80). Thirty-six (10.84%) patients were lost from follow-up with an incidence rate of 6.47 (95% CI: 4.67, 8.97)/1000 Person Months (PM). Homelessness (Adjusted Hazard Ratio (AHR) =2.51, 95%CI: 1.15, 5.45) and treatment enrolment year from 2013 to 2014 (AHR = 3.25, 95% CI: 1.30, 8.13) were significant predictors of LTFU. This study indicated that LTFU among DR-TB registered patients was high in the first six months compared to subsequent months. Homelessness and year of treatment enrolment were independent predictors of LTFU, requiring more economic support to patients in order to ensure treatment completion. This result can be generalized to patients who are using DR-TB treatment in similar settings.
Sections du résumé
BACKGROUND
BACKGROUND
The emergence of Drug-Resistance Tuberculosis (DR-TB) is an increasing global public health problem. Lost to Follow-up (LTFU) from DR-TB treatment remains a major barrier to tuberculosis epidemic control and better treatment outcome. In Ethiopia, evidences on the incidence and predictors of LTFU are scarce. Thus, this study aimed to determine the incidence and identify the predictors of LTFU among DR-TB patients.
METHODS
METHODS
A retrospective follow-up study was conducted among a total of 332 DR-TB patients at the University of Gondar comprehensive specialized hospital. Data were retrieved from patient records from September 2010 to December 2017 and entered in to Epi-data 4.2.0.0 and analysed using Stata14.1 software. The risk was estimated using the Nelson-Aalen cumulative hazard curve. A log-rank test was used for survival comparisons between categories of independent variables. The Gompertz regression model was fitted, and hazard ratio with a 95% confidence interval (CI) was used to measure the strength of associations. Variables with less than 0.05 p-values in the multivariable model were considered as significantly associated with LTFU.
RESULTS
RESULTS
Among a total of 332 patient records reviewed, 206 (62.05%) were male. The median age was 30 years (Inter Quartile Range (IQR): 23-40). Forty-one (12.35%) of the participants had no history of TB treatment, while a quarter of were TB-HIV co-infected. Closely all (92.17%) of the patients had pulmonary tuberculosis. The median follow up time was 20.37 months (IQR: 11.02, 21.80). Thirty-six (10.84%) patients were lost from follow-up with an incidence rate of 6.47 (95% CI: 4.67, 8.97)/1000 Person Months (PM). Homelessness (Adjusted Hazard Ratio (AHR) =2.51, 95%CI: 1.15, 5.45) and treatment enrolment year from 2013 to 2014 (AHR = 3.25, 95% CI: 1.30, 8.13) were significant predictors of LTFU.
CONCLUSION
CONCLUSIONS
This study indicated that LTFU among DR-TB registered patients was high in the first six months compared to subsequent months. Homelessness and year of treatment enrolment were independent predictors of LTFU, requiring more economic support to patients in order to ensure treatment completion. This result can be generalized to patients who are using DR-TB treatment in similar settings.
Identifiants
pubmed: 31533661
doi: 10.1186/s12879-019-4447-8
pii: 10.1186/s12879-019-4447-8
pmc: PMC6751642
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
817Références
Clin Infect Dis. 2008 Jun 15;46(12):1844-51
pubmed: 18462099
Int J Tuberc Lung Dis. 2012 Jun;16(6):805-11
pubmed: 22390880
Tuberculosis (Edinb). 2012 Sep;92(5):397-403
pubmed: 22789497
Int J Tuberc Lung Dis. 2013 Mar;17(3):299-307
pubmed: 23211716
PLoS One. 2013 Dec 13;8(12):e83480
pubmed: 24349518
Int J Tuberc Lung Dis. 2014 Apr;18(4):441-8
pubmed: 24670700
PLoS One. 2015 Mar 18;10(3):e0118919
pubmed: 25785451
Lancet. 2015 May 2;385(9979):1799-1801
pubmed: 25814376
BMC Public Health. 2015 Mar 25;15:291
pubmed: 25880829
PLoS One. 2015 Jul 13;10(7):e0132543
pubmed: 26167891
PLoS One. 2015 Aug 24;10(8):e0135802
pubmed: 26301748
Public Health Action. 2014 Oct 21;4(Suppl 2):S41-6
pubmed: 26393097
Thorax. 2015 Dec;70(12):1181-8
pubmed: 26506854
Emerg Infect Dis. 2016 Mar;22(3):491-502
pubmed: 26889786
Trop Med Int Health. 2017 Mar;22(3):351-362
pubmed: 27978594
Int J Tuberc Lung Dis. 2017 Jan 1;21(1):23-31
pubmed: 28157461
BMC Infect Dis. 2017 Mar 20;17(1):219
pubmed: 28320336
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28331043
Public Health Action. 2017 Jun 21;7(2):116-122
pubmed: 28695084
BMC Infect Dis. 2017 Aug 4;17(1):543
pubmed: 28778187
Bull World Health Organ. 2017 Aug 1;95(8):584-593
pubmed: 28804170